Banoxantrone Dihydrochloride | CAS#252979-56-9 | cytotoxin

MedKoo Cat#: 533234 | Name: Banoxantrone Dihydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Banoxantrone Dihydrochloride is a hypoxia-activated prodrug of topoisomerase II inhibitor. Banoxantrone (AQ4N) is a prototype hypoxia selective cytotoxin that is activated by haem containing reductases such as inducible nitric oxide synthase (iNOS).

Chemical Structure

Banoxantrone Dihydrochloride

CAS#252979-56-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 533234

Name: Banoxantrone Dihydrochloride

CAS#: 252979-56-9 (HCl)

Chemical Formula: C22H30Cl2N4O6

Exact Mass: 516.1542

Molecular Weight: 517.40

Elemental Analysis: C, 51.07; H, 5.84; Cl, 13.70; N, 10.83; O, 18.55

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

136470-65-0 (free) 252979-56-9 (HCl)

Synonym

Banoxantrone Dihydrochloride; Banoxantrone HCl; AQ4N dihydrochloride; AQ4N HCl

IUPAC/Chemical Name

1,4-Bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride

InChi Key

SBWCPHUXRZRTDP-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H28N4O6.2ClH/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30;;/h5-8,23-24,27-28H,9-12H2,1-4H3;2*1H

SMILES Code

O=C1C2=C(C(O)=CC=C2O)C(C3=C(NCC[N+](C)(C)[O-])C=CC(NCC[N+](C)(C)[O-])=C13)=O.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 517.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Huang KY, Weng WH, Huang X, Huang HX, Noreldeen HAA, Deng HH, Chen W. Gold Nanocluster-Based Fluorometric Banoxantrone Assay Enabled by Photoinduced Electron Transfer. Nanomaterials (Basel). 2022 May 30;12(11):1861. doi: 10.3390/nano12111861. PMID: 35683717; PMCID: PMC9182391. 2: Sun T, Li J, Zeng C, Luo C, Luo X, Li H. Banoxantrone Coordinated Metal- Organic Framework for Photoacoustic Imaging-Guided High Intensity Focused Ultrasound Therapy. Adv Healthc Mater. 2023 Jan;12(2):e2202348. doi: 10.1002/adhm.202202348. Epub 2022 Nov 7. PMID: 36281898. 3: Sun Y, Zhao D, Wang G, Wang Y, Cao L, Sun J, Jiang Q, He Z. Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development. Acta Pharm Sin B. 2020 Aug;10(8):1382-1396. doi: 10.1016/j.apsb.2020.01.004. Epub 2020 Jan 13. PMID: 32963938; PMCID: PMC7488364. 4: Mehibel M, Singh S, Cowen RL, Williams KJ, Stratford IJ. Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase. Oncol Rep. 2016 Apr;35(4):1925-32. doi: 10.3892/or.2016.4555. Epub 2016 Jan 13. PMID: 26782976; PMCID: PMC4774668. 5: Hou X, Chang YX, Yue YX, Wang ZH, Ding F, Li ZH, Li HB, Xu Y, Kong X, Huang F, Guo DS, Liu J. Supramolecular Radiosensitizer Based on Hypoxia-Responsive Macrocycle. Adv Sci (Weinh). 2022 Feb;9(6):e2104349. doi: 10.1002/advs.202104349. Epub 2022 Jan 7. PMID: 34994113; PMCID: PMC8867162. 6: Wang X, Ding H, Li Z, Peng Y, Tan H, Wang C, Huang G, Li W, Ma G, Wei W. Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects. Signal Transduct Target Ther. 2022 Mar 16;7(1):74. doi: 10.1038/s41392-022-00894-3. PMID: 35292619; PMCID: PMC8924195. 7: Okamoto K, Nozawa H, Sonoda H, Kaneko M, Ishihara S. Combinatory anti-tumor activities of 1,4-bis[2-(dimethylamino)ethylamino]-5,8-dihydroxyanthracene-9,10-dione (AQ4) and temsirolimus against colorectal cancer cells. J Cancer Res Clin Oncol. 2022 Oct 11. doi: 10.1007/s00432-022-04383-6. Epub ahead of print. PMID: 36220941. 8: Mehibel M, Singh S, Chinje EC, Cowen RL, Stratford IJ. Effects of cytokine- induced macrophages on the response of tumor cells to banoxantrone (AQ4N). Mol Cancer Ther. 2009 May;8(5):1261-9. doi: 10.1158/1535-7163.MCT-08-0927. Epub 2009 May 12. PMID: 19435866. 9: Manley E Jr, Waxman DJ. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther. 2013 Feb;344(2):368-77. doi: 10.1124/jpet.112.200089. Epub 2012 Nov 28. PMID: 23192656; PMCID: PMC3558827. 10: McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol). 2007 Aug;19(6):427-42. doi: 10.1016/j.clon.2007.03.006. Epub 2007 May 4. PMID: 17482438. 11: Yang L, Zhu Y, Liang L, Wang C, Ning X, Feng X. Self-Assembly of Intelligent Nanoplatform for Endogenous H2S-Triggered Multimodal Cascade Therapy of Colon Cancer. Nano Lett. 2022 May 25;22(10):4207-4214. doi: 10.1021/acs.nanolett.2c01131. Epub 2022 May 9. PMID: 35532346. 12: Boyle RG, Travers S. Hypoxia: targeting the tumour. Anticancer Agents Med Chem. 2006 Jul;6(4):281-6. doi: 10.2174/187152006777698169. PMID: 16842231. 13: Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des. 2003;9(26):2131-54. doi: 10.2174/1381612033454117. PMID: 14529410. 14: Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH, Smaill JB, Patterson AV, Ding K. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer. 2014 Feb;33(2):80-6. doi: 10.5732/cjc.012.10285. Epub 2013 Jul 12. PMID: 23845143; PMCID: PMC3935009. 15: Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia- activated prodrugs. Cancer Chemother Pharmacol. 2016 Mar;77(3):441-57. doi: 10.1007/s00280-015-2920-7. Epub 2016 Jan 25. PMID: 26811177; PMCID: PMC4767869. 16: Li Y, Zhao L, Li XF. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy. Front Oncol. 2021 Jul 29;11:700407. doi: 10.3389/fonc.2021.700407. PMID: 34395270; PMCID: PMC8358929. 17: Wang Y, Tang Y, Du Y, Lin L, Zhang Z, Ou X, Chen S, Wang Q, Zou J. Genetically engineered bacteria-mediated multi-functional nanoparticles for synergistic tumor-targeting therapy. Acta Biomater. 2022 Sep 15;150:337-352. doi: 10.1016/j.actbio.2022.07.056. Epub 2022 Aug 2. PMID: 35931281. 18: Wang X, Cheng Y, Han X, Yan J, Wu Y, Song P, Wang Y, Li X, Zhang H. Functional 2D Iron-Based Nanosheets for Synergistic Immunotherapy, Phototherapy, and Chemotherapy of Tumor. Adv Healthc Mater. 2022 Oct;11(19):e2200776. doi: 10.1002/adhm.202200776. Epub 2022 Aug 12. PMID: 35912918. 19: Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 2007 Aug;19(6):397-417. doi: 10.1016/j.clon.2007.03.010. Epub 2007 May 2. PMID: 17478086. 20: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PMID: 19536362.